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The utilization of MRI in the workup of breast cancer has played a controversial role in the surgical treatment of this disease. With
the higher resolution of breast tissue aﬀorded, additional lesions are being identiﬁed that often warrant additional procedures,
subsequently aﬀecting the decision to proceed with breast conservation therapy versus mastectomy. In this paper, a literature
review is presented to help illuminate some of the beneﬁts and pitfalls of employing MRI as a diagnostic tool in the care of breast
cancer, while additionally providing insight into the management alterations this imaging modality can engender. Though further
research is required in a randomized prospective form to fully answer this question, evidence for and against its use continues to
mount, especially for select patient groups.
1.Introduction
The workup for a newly discovered breast cancer has been
changing over the last decade and increasingly includes the
use of preoperative magnetic resonance imaging (MRI) for
staging purposes. MRI is clearly useful in selected patients:
thosewithBRCAmutations,youngwomenwithdensebreast
tissue and high risk of cancer, and women with malignant
axillary nodes but no evidence of a primary lesion [1]. MRI
use in high-risk women (cumulative lifetime risk of 15% or
more) has been shown to be more sensitive (79.5% versus
33.3%) but less speciﬁc (89.8% versus 95.0%) for detecting
cancerous lesions when compared to mammography and is
recommended as an adjunct for high-risk patients [2]. The
American Cancer Society published an update of guidelines
in 2007 which recommends routine use of MRI in patients
with a 20–25% lifetime risk of breast cancer; however it
does not recommend for or against screening for women
with a personal history of breast cancer, carcinoma in
situ, atypical hyperplasia, or extremely dense breasts on
mammography [3]. Predictably, there has been a divergence
in practice patterns concerning the use of MRI in the
preoperative setting for these nonhigh-risk patients, and as
of yet there is a paucity of substantial supporting evidence
for either approach. While some have endorsed the addition
of MRI to the workup of new breast cancers, others have
cautioned that the technology should not be adopted until
large-scale clinical trials could assess its eﬀect on surgical
management and cost [4]. Despite this controversy, many
centers appear to be routinely using the technology as an
adjunct to mammography and ultrasound, and research is
beginning to emerge which demonstrates that it may have
ad e l e t e r i o u se ﬀect, in that many women are undergoing
unnecessary surgical procedures due to MRI ﬁndings [5–
7]. Since the publication of an NIH consensus statement
in 1991, breast conservation therapy (BCT) has been the
preferred treatment for early-stage breast cancer [8]. Before
the breast MRI era, survival has been shown to be equivalent
between breast conservation surgery and mastectomy for
early-stage breast cancer [9, 10]. However, providers may
now be recommending additional mastectomies and even
bilateral mastectomies due to ﬁndings of MRI scans [11, 12].
The aim of this paper is to examine the impact MRI has on
the surgical decision of BCT versus mastectomy.2 International Journal of Surgical Oncology
2. MRI Leadingto Change in
SurgicalManagement
Because there is concern in the surgical and radiologic
community that MRI may be resulting in unnecessary
operations, several papers have been published in recent
years which attempt to examine this interaction [13–23].
The ﬁndings of these individual studies are summarized
in Table 1. In 2008, Solin et al. added to this literature by
examining routine use of pre-operative MRI. Data from this
study noted an increase in ipsilateral and bilateral mastec-
tomies, more extensive lumpectomies, increased workup for
patients, increased costs, and increased delays to surgery
[6]. Three years before, the same author examined several
prognostic elements between patients who had and had not
received MRI and found no diﬀerence in 8-year rates of
local recurrence, contralateral breast cancer, overall survival,
cause-speciﬁc survival or freedom from distant metastases
[5]. This was despite the fact that the MRI group was slightly
younger and had more favorable tumor characteristics than
the control group. Likewise, a group at the Mayo Clinic
Rochester examined trends in their treatment of breast
cancer over a ten-year period (1997–2006). They found that
the general trend for mastectomy decreased over the years
from 1996 to 2003 but increased again from 2003 through
2006—a trend which occurred both in the group which
had received MRI and the group which had not [24]. MRI
use increased drastically from the years between 2003 and
2006 as well. They noted both the surgical date and MRI
as independent predictors of mastectomy in their patients.
Alsoofnote,thepaperraisedtheissueofpatientexpectation,
citing unpublished data from a survey conducted on 227 of
their patients which revealed that 91% of patients felt the
technology was reassuring and had a positive impact on their
care [22].
In 2007 Bilimoria et al. published a study that suggested
MRI should have a role in routine staging evaluation of
newly identiﬁed breast cancers. The study found a beneﬁcial
change in surgical management in 9.7% of patients [22].
However, there was a false-positive rate of 78.0% from MRI
guided biopsies, and it is possible many of these additional
lesions detected by MRI may have been adequately managed
by adjuvant chemotherapy and radiation. Likewise, in 2008
Grobmyer et al. suggested that routine MRI combined with
MRI guided biopsies could reduce high re-excision rates.
In their study, MRI use led to 25 biopsies in 79 women,
44% of which were positive for cancer, leading to a change
in management for 19% of women [23]. While again the
study notes a positive change in surgical management for a
number of women, it is unclear whether these lesions would
have been adequately treated with adjuvant chemotherapy
and radiation. More concerning, the study suggests that
routine MRI and frequent biopsies could become standard
practice but ignores the overwhelming cost implications of
this suggestion.
Other studies have not shown a signiﬁcant diﬀerence
between rates of mastectomy in patients who receive MRI
and those that do not; however there is usually still some
component of additional operations that occur in the MRI
groupsimplyduetothescan.Forinstance,Limetal.contend
that MRI does not lead to an increase in mastectomy;
however they do admit that unnecessary surgical procedures
are likely performed in patients due to benign lesions found
with MRI that are indistinguishable from malignancy. In
their study, surgical management changed due to use of pre-
operative MRI in 84 of 535 patients (15.7%); 47 of those
patients were identiﬁed as having additional malignancy
while the other 37 had benign lesions [25]. The study also
attempted to examine diﬀerences between patients to ﬁnd
those most appropriate for MRI, but analyses of age, T
stage pathological diagnosis, histology, and expression of
hormonal status showed no diﬀerence between groups. This
study did not address the recurrence rates between groups
and did not speculate on the possibility that some of the
“correctly”managedpatientsafterMRImaynothaveneeded
the additional surgery after chemotherapy or radiation.
MRI has proven useful for detection of multifocal (les-
ions in the same quadrant) and multicentric (lesions in a
separate quadrant) disease; however the question remains
of how much of this additional detected disease is clinically
relevant. A meta-analysis from 2008 found that detection
of multifocal or multicentric disease ranged from 6% to
34% [26]. This is in large part a driving factor in the
decision to alter surgical management; if a lesion appears
on MRI to be larger or more extensive than originally
thought, the surgeon frequently must alter the operative
plan. In the same meta-analysis, patients in whom MRI
aﬀected surgical management ranged from 7.8% to 33.3%.
The study found that 8.1% of patients were converted from
BCT to mastectomy and 11.3% of patients were converted
from BCT to more extensive surgery (deﬁned as wider
excision, additional excision, or mastectomy) [26]. A small
percentage of these patients experienced a change in surgery
due to ultimately benign lesions (false positive MRIs). The
study concluded that for every two women in which MRI
detected a true additional lesion, one woman would have
a false positive ﬁnding in the aﬀected breast. The authors
noted that a limitation of many studies they reviewed was
failure to report criteria for MRI deﬁnition of multifocal or
multicentric disease, interpretation criteria for test positives,
and additional information about women selected for MRI
staging from the pool of all women with breast cancer.
They further recommend that MRI should not be performed
in centers where detection of additional lesions cannot be
followed up by MRI-guided percutaneous biopsy.
3.EffectonContralateralOperations
Not only does MRI lead to larger operations in the ipsilateral
breast,butbecauseitisfrequentlyabilateralstudy,contralat-
eral operations may also be increasing as a result. Sorbero
et al. published data in 2009 that demonstrated a signiﬁcant
correlation between MRI and contralateral prophylactic
mastectomy [27]. Although their study did not evaluate
causation,womenwhohadreceivedbilateralMRIweremore
than twice as likely to undergo contralateral prophylactic
mastectomy. Likewise, a meta-analysis demonstrated that
MRI only detected abnormalities in nearly ten percent ofInternational Journal of Surgical Oncology 3
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Table 2: Change in Outcome in patients with MRI versus no MRI.
Surgical outcome Did not have MRI Had MRI P
No. (%) with outcome No. (%) with outcome
Mann et al. [35] Re-excision 25/168 (14.9) 5/99 (5.1) .01
Turnbull et al. [7] Re-excision/re-operation 156/807 (19.3) 153/816 (18.8) .77
Bleicher et al. [31] Positive margins 33/239 (13.8) 11/51 (21.6) .20
Hwang et al. [30] 8-year recurrence (2.5) (1.8) .67
Pengel et al. [20] Positive margins 35/180 (19.4) 22/159 (13.8) .17
Solin et al. [5] 8-year survival 471/541(87) 185/215 (86) .51
Fischer et al. [17] recurrence 9/133 (6.8) 1/86 (1.2) <.001
patients studied, less than half of which were ultimately
cancerous [28]. This yielded an incremental cancer detection
rate of 4.1%, PPV of 47.9%. A similar study had relatively
low false positive rates for additional lesions found by MRI
(6.6%); however the authors note that tissue sampling of
each additional ﬁnding likely contributed to this low rate
[29].
4. Effect on Rate of Recurrence
andReoperation
Recurrence is an undoubtedly disappointing complication
of breast cancer surgery, and therefore it is essential that
pre-operative imaging is able to discern the accurate tumor
size. If the margins of the resected specimen are involved
or are too narrow, the surgeon is obligated to reoperate—
causing additional cost and emotional burden to the patient.
Most studies have found that re-operation in patients who
undergo pre-operative MRI is not signiﬁcantly diﬀerent than
re-operation in patients who do not undergo pre-operative
MRI [5, 7, 20, 30, 31]. It is speculated that many of the
additional lesions found on MRI are adequately managed
by adjuvant chemotherapy and radiation, accounting for the
equivalence of recurrence in these groups [7]. One paper
examined recurrence rates in women studied by MRI and
thosewhowerenotandnotedsigniﬁcantlyfewerrecurrences
in those women who received pre-operative MRI [32].
However, the groups in the study were not matched, and
those who had pre-operative MRI had less advanced lesions
than the comparison group. The ﬁndings of groups who
examined survival rates, recurrence rates, and margin status
are summarized in Table 2.
5.Cost of PreoperativeMRI
Another salient consideration in the use of routine pre-
operative MRI is the cost of the procedure. Additionally,
one must factor the attendant cost of additional biopsies
and other workup when suspicious lesions are found.
Very few papers address this issue directly, although some
make mention of the costs associated with the technology.
Moore et al. studied the issue of cost of MRI per quality
adjusted life year (QALY) for women at high risk per Claus
model deﬁnition and found that MRI screening did not
approach cost-eﬀectiveness even when using a threshold of
$120,000/QALY [33]. Costs were estimated using Medicare
and Medicaid reimbursement data. The authors additionally
cited data from a similar study that examined only BRCA
carriers, in which case MRI was cost eﬀective using a
threshold of $100,000/QALY.
6. Possible Applications
It is likely that there are speciﬁc groups that will arise in
future studies who would beneﬁt from the inclusion of MRI
inthepre-operativeworkupofnewlyidentiﬁedbreastcancer.
For instance, the use of MRI as an eligibility-screening tool
for patients selected to have partial breast irradiation (PBI) is
intriguing,asitcouldpotentiallypreventtheundertreatment
of occult malignancies. In a study by Godinez et al. from
2008 of 79 patients, it was suggested that pre-operative
MRI should be performed to prevent such an unfortunate
outcome[18].Thesesentimentswereechoedinapublication
by Al-Hallaq et al. where a positive predictive value for MRI
of 72% was found in identifying such occult malignancies
[34]. Another recently published paper suggests a subset of
patientsthatmayhaveparticularbeneﬁtfromtheadditionof
MRI. Mann et al. examined a patient population composed
entirely of individuals with invasive lobular carcinoma (ILC)
of the breast. In their retrospective cohort study, they found
that patients with ILC who did not receive MRI were far
more likely to undergo re-excision than the patients who had
received pre-operative MRI (OR 3.64, P = .01) [35]. Due to
the relative minority of ILC patients compared to the more
common ductal carcinoma patients, it would be diﬃcult to
pursue large randomized controlled trials to further examine
this phenomenon. As more researchers study MRI and its
impact on patients with varied breast carcinomas, we may
further elucidate patient subsets in which this technology is
most appropriate.
7. Conclusion
MRI is a relatively new technology that has proven useful for
detecting additional lesions in the pre-operative workup for
breast cancer. However, while highly sensitive to additional
lesions, it is less speciﬁc than mammography and results in
many false positive biopsies and surgeries. It appears at theInternational Journal of Surgical Oncology 5
currenttimethattheroutineuseofpre-operativeMRImight
not contribute to an increased survival and cure rates and
could have a negative impact in terms of patient anxiety
as well as cost to the patient and health care system. It is
likely that there is a not yet delineated patient population
thatwouldgreatlybeneﬁtfromtheuseofpre-operativeMRI,
but as no study has been able to determine what additional
criteria would help stratify those patients. It is clear from a
review of the literature that randomized trials are needed to
further elucidate the role MRI should play in the evaluation
of women with breast cancer.
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